In the dyslipidemia treatment market, the combination drug market that combines 'Statin' and Ezetimibe' showed rapid growth. Despite COVID-19 outbreak, the sales continued high. In the past five years, sales have increased by six times. Hanmi's Rosuzet and MSD's Atozet led the uptrend.

According to the drug research institute UBIST on the 25th, the prescription size of the lipid-regulator combination last year was ￦633.5 billion, an increase of 21.0% from the previous year. The prescription market for lipid-regulating drugs increased by 10.2% and 15.1%, respectively, compared to the previous year in 2018 and 2019, but the growth trend further rose last year.

It showed the most remarkable